Author name: Leonardo Arias

While most BioSpace LinkedIn poll respondents believe the job market won’t improve until at least 2027, two industry experts are optimistic a turnaround could start sooner. They discuss early signals of recovery and challenges that remain.

Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 combined jobs hit just 13% of that target in 2024. Ten awardees had reported layoffs last year, including Charles River Laboratories and Moderna.

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth disorder.

The ruling removes a barrier to a deal the FTC claims will eliminate competition in the outsourced hydrophilic coatings market.

Major payers with a presence in the ACA, Medicare or Medicaid posted an average operating margin of -1.4% in the third quarter. The market “continues to be challenging,” complicating margin recovery plans, one expert said.

The appointment of Pazdur as CDER head comes shortly after the surprise ousting of George Tidmarsh and should quiet many of the “lingering uncertainties” surrounding the FDA, wrote one industry analyst.

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

The company also posted weaker third-quarter results, but CEO David Fischel said orders for the new GenesisX system, when fully launched, would outpace the rate for an older model.

In 2025, landmark obesity drug deals, China’s biotech surge, and AI’s deeper integration into pharma operations drove a year of transformation and renewed momentum for life sciences.

C-suite executives surveyed said they think new technology leadership roles will become more important in the next three years, according to a report from the Healthcare Financial Management Association.